Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. 1998

A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan.

BACKGROUND Natural cytotoxicity mediated by natural killer (NK) cells is believed to play an important role in host anticancer defense mechanisms. The aim of this study was to examine the prognostic significance of NK cell activity after hepatectomy in patients with hepatocellular carcinoma. METHODS The NK cell activity in 210 patients with hepatocellular carcinoma was measured and evaluated in relation to clinicopathologic variables using univariate and multivariate analyses. RESULTS The NK cell activity was decreased significantly in hepatocellular carcinoma patients compared with the control groups (P < 0.001). No correlation was observed between NK cell activity and the clinicopathologic variables. Multivariate analyses indicated that NK cell activity as well as intrahepatic metastases, platelet count, and serum albumin level were independent prognostic factors. CONCLUSIONS This study suggests that the preoperative NK cell activity will help predict recurrence and prognosis after hepatectomy in patients with hepatocellular carcinoma.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006498 Hepatectomy Excision of all or part of the liver. (Dorland, 28th ed) Hepatectomies
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
May 1989, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
November 2014, Medical oncology (Northwood, London, England),
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
December 2014, Annals of surgical oncology,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
December 2014, Cancer immunology research,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
August 1998, Archives of otolaryngology--head & neck surgery,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
November 2009, Ai zheng = Aizheng = Chinese journal of cancer,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
November 1986, Zhonghua zhong liu za zhi [Chinese journal of oncology],
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
April 2018, Oncology letters,
A Taketomi, and M Shimada, and K Shirabe, and K Kajiyama, and T Gion, and K Sugimachi
February 2001, The American journal of gastroenterology,
Copied contents to your clipboard!